Abstract
Infantile hemangiomas, the most common tumors of infancy, are vascular tumors characterized by rapid proliferation of endothelial cells during the first few months of postnatal life followed by slow spontaneous involution, whose molecular pathogenesis remains unclear. The recent identification of developmental expression of vascular lineage-specific markers prompted us to characterize infantile hemangiomas for the expression of lymphatic endothelial hyaluronan receptor-1 (LYVE-1), Prox-1, CD31 and CD34. We found that LYVE-1, a specific marker for normal and tumor-associated lymphatic vessels, was strongly expressed in tumor cells of infantile hemangiomas (n=28), but not in other vascular tumors including pyogenic granulomas (n=19, P<0.0001) or intramuscular hemangiomas (n=9), using LYVE-1/CD31 double immunostains. Whereas LYVE-1 expression was detected on the endothelial cells of all proliferating infantile hemangiomas, this lymphatic marker was absent from the lesional capillaries during involution in the majority of cases (P=0.0009). The majority of LYVE-1+ endothelial cells also expressed CD34, but were negative for the lymphatic-specific homeobox protein Prox-1. Based on coexpression of both LYVE-1 and the blood vascular marker CD34, we propose that the endothelial cells in proliferating infantile hemangioma are arrested in an early developmental stage of vascular differentiation. The immature, incompletely differentiated immunophenotype of proliferating infantile hemangiomas may contribute to their rapid growth during the first few months of life.
Similar content being viewed by others
Main
Infantile hemangiomas, the most common tumor of infancy, are benign vascular proliferations composed of densely packed capillaries composed of endothelial cells and pericytes expanding in a lobular pattern.1 In contrast to vascular malformations, infantile hemangiomas are usually absent or inconspicuous at birth and are characterized by a remarkably predictable biologic behavior: rapid postnatal proliferation and slow spontaneous involution.2 Involution is characterized by apoptosis and disappearance of capillaries, with replacement by loose fibrous or fibro-fatty tissue. Infantile hemangiomas occur more commonly in premature Caucasian female infants,3 but are distinguished from other vascular tumors and malformations by their specific expression of erythrocyte-type glucose transporter protein, GLUT-1.4 The molecular pathogenesis of infantile hemangiomas remains a mystery to date, partly due to a confusing nomenclature of vascular birthmarks5 and to the lack of lineage-specific vascular differentiation markers.
Several recent studies have investigated the cellular and molecular basis of these tumors, leading to the proposal of distinct but controversial mechanisms of pathogenesis. It has been proposed that infantile hemangiomas are due to the clonal proliferation of endothelial cells based on the analysis of X-chromosome inactivation patterns, indicating that a single progenitor cell may give rise to the infantile hemangioma endothelial cell population.6, 7 Most recently, it was found that this population of endothelial progenitor cells coexpresses CD34 and the progenitor cell marker CD133, as detected by flow cytometry in 11/12 proliferating infantile hemangioma specimens.8 It has also been suggested that infantile hemangiomas are the products of somatic mutations in one or more genes that regulate endothelial cell growth.9 Although the vast majority of infantile hemangiomas occur sporadically, several kindreds have been identified to segregate as an autosomal dominant trait with high penetrance, and FGFR4, PDGFRB and Flt-4 have been suggested as candidate genes for familial infantile hemangioma.10 Somatic mutations of the kinase domain of the VEGFR2 (FLK1/KDR) gene and of the VEGFR3 (FLT4) gene were found in proliferating infantile hemangiomas.7 These genetic mutations may result in abnormal endothelial cell proliferation and dysregulation of angiogenesis, as evidenced by the activation of the angiopoietin/Tie2 pathway in isolated endothelial cells from proliferating infantile hemangiomas.11 Stimulators of angiogenesis such as VEGF,12 bFGF,13 monocyte chemoattractant protein-114 and insulin-like growth factor 2 (IGF-2)15 are also upregulated in proliferating infantile hemangioma.
In contrast, tissue inhibitor of metalloproteinase-1, an angiogenesis inhibitor,12 and interferon-induced genes were found to be increased during the involution phase.15 The induction of interferon genes provides a clinical rationale for the treatment of life-threatening infantile hemangiomas with recombinant interferon-α-2a, an inhibitor of angiogenesis16 and may explain recently reported observations of rapid involution of infantile hemangiomas after topical applications of the immune modulator imiquimod.17 Interestingly, the epidermis overlying proliferating infantile hemangioma demonstrates reduced interferon-β immunostaining, compared with the epidermis of normal skin, implicating possible paracrine effects of nonendothelial cells in the pathogenesis of infantile hemangioma.18 Recent studies have demonstrated that the vessels of infantile hemangioma and placenta share a unique immunophenotype, as evidenced by expression of GLUT-1, merosin, FcγRII and Lewis Y antigen, leading to a proposal that the precursor cells of infantile hemangioma may originate from placentally derived cells or angioblasts switched to the placental-type vascular phenotype.19
In the present study, we investigated the vascular lineage-specific differentiation of proliferating and of involuting infantile hemangiomas, using several of the newly identified blood vascular and lymphatic endothelial cell markers. We analyzed 62 vascular lesions for the expression of the panendothelial marker CD31, and of the lymphatic endothelial hyaluronan receptor-1 (LYVE-1), a 60 kDa integral membrane glycoprotein, considered to be a specific marker for normal20 and tumor-associated lymphatic vessels.21, 22
Materials and methods
Patient Population and Histological Analyses
All vascular lesions were excised at Arkansas Children's Hospital, Little Rock, during the past 5 years (1999–2003), after informed consent and institutional review board approval were obtained. These vascular lesions included infantile hemangiomas (n=28), pyogenic granulomas (PG) (n=19), intramuscular hemangiomas (small vessel type, n=9), umbilical hemangiomas (n=2), congenital nonprogressive hemangioma (n=1), synovial vascular malformation (n=1) and cherry hemangioma (n=1) (Table 1). Patients (age range 2 months to 5 years) with both proliferating (n=19, mean age 7.8 months) and involuting (n=9, mean age 26.3 months) infantile hemangioma were well represented, with sex and site distribution similar to those reported in large epidemiological studies.23 Two pathologists (SSD and PEN) reconfirmed the diagnosis of all 62 vascular lesions.
Immunofluorescent Stains
Paraffin sections (6 μm thickness) were dewaxed, hydrated and treated with 0.01% protease XXIV (Sigma, St Louis, MO, USA) in phosphate-buffered saline for 20 min at 37°C for all 62 lesions. Sections were double stained using a rabbit polyclonal antibody against human LYVE-120 and a mouse monoclonal anti-human CD31 antibody (Table 2), followed by incubation with the respective secondary antibodies that were labeled with either Texas Red (1:50) or with fluorescein isothiocyanate (1:50) (Jackson ImmunoResearch, West Grove, PA, USA), as previously described.22 Cell nuclei were counterstained with 20 μg/ml Hoechst bisbenzimide (Sigma). Additional immunohistochemical stains were performed using antibodies against CD34, Prox-1, GLUT-1, CD68 or CD11b (Table 2). Fresh-frozen tissue sections were incubated in acetone at −20°C for 2 min and in 80% methanol at 4°C for 5 min, blocked in 12% BSA solution for 20 min prior to incubation with primary antibody in four proliferating infantile hemangiomas, where paraffin section immunostaining for Prox1 and CD11b was not possible. Three observers scored the stained sections for semiquantitative LYVE-1 expression in tumor cells, together with hematoxylin–eosin-stained serial sections. The results were scored as follows, 1+: <10% of lesional vessels positive; 2+: 10–50% of lesional vessels positive; 3+: >50% of lesional vessels positive (Table 3).
Statistical Analysis
The unpaired Student's t-test was used to determine the statistical significance (P-value) of LYVE-1 expression.
Results
LYVE-1 Expression by Endothelial Cells of Proliferating Infantile Hemangiomas
To investigate the lineage-specific differentiation of infantile hemangioma, we examined tissue sections from patients with both proliferating and involuting infantile hemangiomas for markers of lymphatic and blood vascular endothelium. We found that the entire infantile hemangioma lobule showed endothelial positivity for the panendothelial marker CD31 (12) (Figure 1b). Surprisingly, the entire lobule was also strongly positive for LYVE-1 in most cases (Figure 1a). Merged images of LYVE-1 and CD31 revealed a virtually complete overlap of the green and red signals, suggesting that the lesional capillaries coexpressed both LYVE-1 and CD31 (Figure 1c). Normal blood vessels adjacent to infantile hemangiomas did not express LYVE-1 (Figure 1g). We detected LYVE-1 expression in 19/19 (100%) proliferating infantile hemangioma and 5/9 (55.6%) involuting infantile hemangioma (P=0.0009). Although all of the proliferating infantile hemangioma expressed LYVE-1, the lesional capillaries showed a variable immunoreactivity (Figure 1c, e and g). Based on the percentage of lesional capillaries, all tumors were assessed for semiquantitative LYVE-1 expression. The majority (79%) of proliferating infantile hemangiomas showed either >10–50% or >50% of lesional vessels immunoreactive for LYVE-1 (Table 3). High magnification views of immunostains revealed both cytoplasmic and membranous distribution of LYVE-1 (Figure 1h).
To investigate whether LYVE-1 expression was specific for infantile hemangiomas, we examined several other benign vascular tumors for their LYVE-1 immunoreactivity. Compared to proliferating infantile hemangiomas, LYVE-1 expression was focally and weakly detected in only 3/19 (15.8%, P <0.0001) PGs, in a pattern suggestive of normal, intra- and peri-lesional draining lymphatics, whereas the remainder of vascular lesions including intramuscular hemangiomas (9/9), umbilical vascular malformations (2/2), congenital nonprogressive hemangioma (1/1), synovial vascular malformation (1/1), cherry hemangioma (1/1) and reactive angioendotheliomatosis (1/1) were completely negative for LYVE-1. All examined vascular lesions were positive for CD31 (Figure 2). Interestingly, congenital nonprogressive hemangiomas are composed of numerous distinct proliferating capillaries admixed with many thin-walled vessels, suggestive of lymphatic vessels,24 which are in fact strongly LYVE-1 positive (Figure 2g). Umbilical and synovial vascular malformations were negative for GLUT-1 and LYVE-1 (data not shown). The age ranges for patients with other vascular tumors overlapped with those of the infantile hemangioma group (2 months to 5 years) (Table 1). Therefore, LYVE-1 expression is an age-independent phenomenon specific for endothelial cells of proliferating infantile hemangiomas.
Downregulation of LYVE-1 Expression in Infantile Hemangiomas during Involution
Analysis of infantile hemangiomas demonstrated absence of LYVE-1 immunoreactivity from the majority of tumor endothelial cells during involution, whereas CD31 expression remained unchanged (Figure 3). In fact, 4/9 (44.4%) of involuting infantile hemangiomas were completely negative for LYVE-1 expression, and only a few lesional capillaries (<10%) were LYVE-1 immunoreactive in the other cases in contrast to proliferating lesions (P=0.0009) (Table 3). Involuting lesions displayed flattening of endothelium (Figure 3d and h), in contrast to the plump shape of endothelial cells during the proliferative phase (Figure 3b and f). Although the lobular architecture was maintained in some involuting lesions (Figure 3h), LYVE-1 expression was lost as involution proceeded (Figure 3h).
Detection of LYVE-1 Positive Macrophages in Infantile Hemangiomas
We detected numerous LYVE-1+ mononuclear cells in both proliferating (Figure 2a) and involuting infantile hemangioma (Figure 3c and g). To further characterize these cells, we performed double stains with the macrophage markers, CD11b25 and CD6826 and LYVE-1. We found that LYVE-1+ mononuclear cells expressed both CD11b and CD68 in proliferating and involuting infantile hemangiomas (Figure 4), identifying them as macrophages.
Lesional Endothelial Cells are Arrested in Vascular Development
Since lesional capillaries of infantile hemangiomas expressed LYVE-1, a specific lymphatic marker, we assessed these tumors for the expression of the lineage-specific lymphatic homeobox gene, Prox-1, and of the blood vascular-specific marker, CD34. Double immunofluorescence stains for LYVE-1/CD31 and LYVE-1/CD34 in serial sections revealed that LYVE-1+ endothelial cells also express CD34 (Figure 5a and b). Double immunofluorescence stains of serial sections for LYVE-1/CD31 and Prox-1/CD31 revealed that all tumor endothelial cells were negative for Prox-1 (Figure 5c and d). Hence, infantile hemangioma endothelial cells are LYVE-1+, CD31+, CD34+ but Prox-1−. Double stains for LYVE-1/ GLUT-1 clearly demonstrated that the tumor endothelial cells coexpressed both proteins during the proliferative phase (Figure 5e and f).
Discussion
Despite the high prevalence of infantile hemangiomas in the pediatric population, the molecular events leading to rapid proliferation and slow involution of these tumors remain unclear. We demonstrate here that the hyaluronan receptor LYVE-1 is specifically expressed in endothelial cells of infantile hemangioma during the proliferative phase and is downregulated during involution. Moreover, infantile hemangioma endothelial cells are Prox-1−, SLC−, VEGFR-3+, CD31+ and CD34+. This endothelial cell immunophenotype resembles that of the cardinal vein during early normal embryogenesis, at a stage leading to the development of mature blood vessels or to acquiring lymphatic bias27 (Figure 6).
After the initial formation of the vascular system, a subpopulation of venous endothelial cells becomes competent to respond to a lymphatic inducing signal by expressing the homeobox gene Prox-1, at day ∼E9.5.28 Our data suggest that the endothelial cells in infantile hemangiomas display an immature immunophenotype, similar to that in cardinal vein endothelial cell with lymphatic competence, suggesting the endothelial cells are arrested in an early stage of vascular development. This undifferentiated phenotype may explain their rapid proliferation. As infantile hemangiomas regress, the endothelial cells, coincident with downregulation of LYVE-1, attain a more mature immunophenotype, LYVE-1−, Prox-1−, SLC−, VEGFR-3−, CD31+ and CD34+, and develop into mature blood vessels (Figure 6). We hypothesize that somatic mutations may lead to arrested maturation and clonal expansion of infantile hemangioma endothelial cells with an immature immunophenotype.
The isolation of CD133+/CD34+ endothelial progenitor cells from proliferating infantile hemangiomas8 supports the primitive nature of these endothelial cells, since CD133 is expressed by embryonic epithelium (neuroepithelium, kidney and gut)29 and CD34+ endothelial cell precursors (hemangioblasts).30 It has been demonstrated that infantile hemangiomas share expression of GLUT-1, merosin, FcγRII and Lewis Y antigen with human placenta microvasculature,19 further supporting the fetal or embryonic nature of infantile hemangioma endothelial cells. Together, these results and our data suggest an intrinsic defect in infantile hemangioma endothelial cell maturation that may result in their abnormal proliferation.
In summary, our study demonstrates, for the first time, specific expression of LYVE-1 in infantile hemangioma endothelial cells during the proliferative phase and downregulation during the involuting phase. This identifies LYVE-1 as a novel marker for proliferating infantile hemangioma, since GLUT-1 is expressed during both phases.19 Analysis of the specific blood and lymphatic endothelial cell markers, CD34 and Prox-1, respectively, revealed that the endothelial cells of infantile hemangioma have an immunophenotype similar in this regard to that of the embryonic vein during normal vascular development. We propose that infantile hemangioma endothelial cells are arrested in an early stage of vascular differentiation, with important implications for the pathogenesis of rapid postnatal proliferation.
References
Garzon M . Infantile hemangiomas. In: Bolognia J, Jorizz J, Rapini RP (eds). Dermatology. Mosby: London, 2003, pp 1599–1614 Chapter 104.
Bruckner AL, Frieden IJ . Hemangiomas of infancy. J Am Acad Dermatol 2003;48:477–493.
Margileth AM, Museles M . Cutaneous hemangiomas in children. Diagnosis and conservative management. JAMA 1965;194:523–526.
North PE, Waner M, Mizeracki A, et al. GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol 2000;31:11–22.
Mulliken JB, Glowacki J . Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg 1982;69:412–422.
Boye E, Yu Y, Paranya G, et al. Clonality and altered behavior of endothelial cells from hemangiomas. J Clin Invest 2001;107:745–752.
Walter JW, North PE, Waner M, et al. Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma. Genes Chromosomes Cancer 2002;33:295–303.
Yu Y, Flint AF, Mulliken JB, et al. Endothelial progenitor cells in infantile hemangioma. Blood 2003, prepublished online, October 23.
Bischoff J . Monoclonal expansion of endothelial cells in hemangioma: an intrinsic defect with extrinsic consequences? Trends Cardiovasc Med 2002;12:220–224.
Walter JW, Blei F, Anderson JL, et al. Genetic mapping of a novel familial form of infantile hemangioma. Am J Med Genet 1999;82:77–83.
Yu Y, Varughese J, Brown LF, et al. Increased Tie2 expression, enhanced response to angiopoietin-1, and dysregulated angiopoietin-2 expression in hemangioma-derived endothelial cells. Am J Pathol 2001; 159:2271–2280.
Takahashi K, Mulliken JB, Kozakewich HP, et al. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 1994;93:2357–2364.
Chang J, Most D, Bresnick S, et al. Proliferative hemangiomas: analysis of cytokine gene expression and angiogenesis. Plast Reconstr Surg 1999;103:1–9.
Isik FF, Rand RP, Gruss JS, et al. Monocyte chemoattractant protein-1 mRNA expression in hemangiomas and vascular malformations. J Surg Res 1996;61:71–76.
Ritter MR, Dorrell MI, Edmonds J, et al. Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis. Proc Natl Acad Sci USA 2002;99:7455–7460.
Ezekowitz RA, Mulliken JB, Folkman J . Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992;326:1456–1463.
Martinez MI, Sanchez-Carpintero I, North PE, et al. Infantile hemangioma: clinical resolution with 5% imiquimod cream. Arch Dermatol 2002;138:881–884 discussion 884.
Bielenberg DR, Bucana CD, Sanchez R, et al. Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor, IFN-beta. Int J Oncol 1999;14:401–408.
North PE, Waner M, Mizeracki A, et al. A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol 2001;137:559–570.
Banerji S, Ni J, Wang SX, et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 1999;144:789–801.
Beasley NJ, Prevo R, Banerji S, et al. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res 2002;62:1315–1320.
Dadras SS, Paul T, Bertoncini J, et al. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 2003;162:1951–1960.
Jacobs A . Strawberry hemangiomas: the natural history of the untreated lesion. Calif Med 1957;86:8–10.
North PE, Waner M, James CA, et al. Congenital nonprogressive hemangioma: a distinct clinicopathologic entity unlike infantile hemangioma. Arch Dermatol 2001;137:1607–1620.
Corbi AL, Kishimoto TK, Miller LJ, et al. The human leukocyte adhesion glycoprotein Mac-1 (complement receptor type 3, CD11b) alpha subunit. Cloning, primary structure, and relation to the integrins, von Willebrand factor and factor B. J Biol Chem 1988;263:12403–12411.
Holness CL, Simmons DL . Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood 1993;81:1607–1613.
Oliver G, Detmar M . The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature. Genes Dev 2002;16:773–783.
Wigle JT, Oliver G . Prox1 function is required for the development of the murine lymphatic system. Cell 1999;98:769–778.
Corbeil D, Roper K, Hellwig A, et al. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 2000;275:5512–5520.
Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34 (+) cells identifies a population of functional endothelial precursors. Blood 2000;95:952–958.
Acknowledgements
We thank L Janes, L Nguyen and A Mizeracki for expert technical assistance; K Alitalo for providing Prox1 antibodies; and DG Jackson for the gift of LYVE-1 antibody. This work was supported by NIH/NCI Grants CA69184, CA86410 and CA91861 (MD), by an NIH Pathology Training Grant (SSD), and by the Cutaneous Biology Research Center through the Massachusetts General Hospital/Shiseido Co. Ltd. Agreement (MD).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dadras, S., North, P., Bertoncini, J. et al. Infantile hemangiomas are arrested in an early developmental vascular differentiation state. Mod Pathol 17, 1068–1079 (2004). https://doi.org/10.1038/modpathol.3800153
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/modpathol.3800153
Keywords
This article is cited by
-
Evaluation of digital image analysis as a supportive tool for the stratification of head and neck vascular anomalies
European Archives of Oto-Rhino-Laryngology (2020)
-
Medical Management of Vascular Anomalies
Current Treatment Options in Pediatrics (2018)
-
The expression and function of miR-424 in infantile skin hemangioma and its mechanism
Scientific Reports (2017)
-
Integrative meta-analysis identifies microRNA-regulated networks in infantile hemangioma
BMC Medical Genetics (2016)
-
Urinary matrix metalloproteinases-2/9 in healthy infants and haemangioma patients prior to and during propranolol therapy
European Journal of Pediatrics (2012)